Alnylam Pharmaceuticals' Research & Development rose 32.44% to $358.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 13.62%. This contributed to the annual value of $1.1 billion for FY2024, which is 12.13% up from last year.
Alnylam Pharmaceuticals' Research & Development amounted to $358.8 million in Q3 2025, which was up 10.87% from $323.6 million recorded in Q2 2025.
Alnylam Pharmaceuticals' 5-year Research & Development high stood at $358.8 million for Q3 2025, and its period low was $169.9 million during Q1 2022.
Moreover, its 3-year median value for Research & Development was $270.9 million (2024), whereas its average is $279.8 million.
Per our database at Business Quant, Alnylam Pharmaceuticals' Research & Development skyrocketed by 35.96% in 2021 and then decreased by 8.61% in 2022.
Alnylam Pharmaceuticals' Research & Development (Quarterly) stood at $229.1 million in 2021, then increased by 14.40% to $262.0 million in 2022, then climbed by 3.86% to $272.1 million in 2023, then climbed by 10.30% to $300.2 million in 2024, then surged by 32.44% to $358.8 million in 2025.
Its last three reported values are $358.8 million in Q3 2025, $323.6 million for Q2 2025, and $265.1 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value